A Closer Look at 5 Analyst Recommendations For Beam Therapeutics
Portfolio Pulse from Benzinga Insights
Beam Therapeutics (NASDAQ:BEAM) has received mixed analyst ratings over the past three months, with a recent increase in the average 12-month price target to $53.2. Analysts have varied in their recommendations, with some maintaining or raising their ratings, while others have lowered them. Despite challenges in revenue growth and profitability, Beam Therapeutics continues to develop its genetic medicine technology.
August 22, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Beam Therapeutics has received mixed analyst ratings, with a recent increase in the average price target to $53.2. Analysts have varied in their recommendations, with some maintaining or raising their ratings, while others have lowered them. The company faces challenges in revenue growth and profitability.
The mixed analyst ratings and increased average price target suggest a neutral short-term impact on Beam Therapeutics' stock price. While some analysts are bullish, others have lowered their ratings, reflecting uncertainty. The company's financial challenges, such as declining revenue and low profitability, may offset positive sentiment from the price target increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100